Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune Checkpoint Inhibition Clear all
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

NCT03206073
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
Interventions
Durvalumab, Tremelimumab, Pexa-Vec
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

NCT03076554
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma
Interventions
Avelumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

NCT04417660
View directory record Official record
Conditions
Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
Interventions
M7824
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

NCT06548789
View directory record Official record
Conditions
Melanoma
Interventions
Prebiotic Xnack Packouts
Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer

NCT04560686
View directory record Official record
Conditions
Resectable Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Bintrafusp Alfa, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

NCT04045613
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

NCT04375228
View directory record Official record
Conditions
Immune-related Adverse Events, Advanced Solid Tumor
Interventions
Rituximab, Tocilizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel

NCT02684461
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

NCT02821754
View directory record Official record
Conditions
Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
Interventions
Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Cryoablation
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

NCT03739931
View directory record Official record
Conditions
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions
mRNA-2752, Durvalumab
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
16
States / cities
San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

NCT06287775
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
43
States / cities
Duarte, California • Irvine, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

NCT03025035
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
Yuan Yuan
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

NCT04577807
View directory record Official record
Conditions
Melanoma
Interventions
Lerapolturev, Anti-PD-1 Checkpoint Inhibitor
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Scottsdale, Arizona • Orlando, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Terminated Phase 1 Interventional

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

NCT04610658
View directory record Official record
Conditions
Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Lurbinectedin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Kissimmee, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05848011
View directory record Official record
Conditions
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Interventions
lorigerlimab, docetaxel, Prednisone
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older · Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Withdrawn Phase 2 Interventional

SBRT as a Vaccination for Metastatic Melanoma

NCT04042506
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 22, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

NCT05123586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
LY3361237, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
19
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Completed No phase listed Observational

Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma

NCT03356470
View directory record Official record
Conditions
Melanoma
Interventions
F-FDG PET/CT
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Timeline
2017 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

NCT03719131
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
Interventions
Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

NCT03729245
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
bempegaldesleukin, sunitinib, nivolumab, cabozantinib
Biological · Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Anchorage, Alaska • Goodyear, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

NCT03693014
View directory record Official record
Conditions
Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
Interventions
Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
Radiation · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

NCT03365791
View directory record Official record
Conditions
Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma
Interventions
PDR001, LAG525
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
San Francisco, California • Port Saint Lucie, Florida • Athens, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

NCT03743766
View directory record Official record
Conditions
Melanoma
Interventions
Relatlimab, Nivolumab, Relatlimab + Nivolumab
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

NCT05915442
View directory record Official record
Conditions
Oligometastatic Prostate Cancer
Interventions
Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Catherine Spina
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jul 22, 2026, 4:05 PM EDT